Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ANTISENSE AND RNAI THERAPEUTICS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL ANTISENSE AND RNAI THERAPEUTICS TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL ANTISENSE AND RNAI THERAPEUTICS TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES
5.3 GLOBAL ANTISENSE AND RNAI THERAPEUTICS TREATMENT MARKET ANALYSIS
6 INDUSTRY INSIGHTS
6.1 DEMOGRAPHIC TRENDS
6.2 KEY PRICING STRATEGIES
6.3 KEY PATIENT ENROLLMENT STRATEGIES
6.4 INTERVIEWS WITH MANUFACTURING COMPANIES
6.5 OTHER KOL SNAPSHOTS
7 REGULATORY FRAMWORK
8 GLOBAL ANTISENSE AND RNAI THERAPEUTICS TREATMENT MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 (NOTE: MARKET VALUE, MARKET VOLUME AND ASP WILL BE PROVIDED FOR ALL SEGMENTS AND SUB SEGMENTS)
8.3 RNA INTERFERENCE
8.3.1 BY MOLECULES
8.3.1.1. PATISIRAN
8.3.1.2. GIVOSIRAN
8.3.1.3. LUMASIRAN
8.3.1.4. MRG-106
8.3.1.5. COBOMARSEN
8.3.1.6. MIRAVIRSEN
8.3.2 BY DRUGS
8.3.2.1. GIVLARRI
8.3.2.2. ONPATTRO
8.3.2.3. OXLUMO
8.3.2.4. OTHERS
8.3.3 BY TYPE
8.3.3.1. DOUBLE-STRANDED RNA VIRUSES (DSRNA)
8.3.3.2. SMALL INTERFERING RNA ( SIRNA)
8.3.3.3. MICRORNAS ( MIRNA)
8.3.4 BY DRUG DELIVERY TECHNOLOGY
8.3.4.1. PULMONARY DRUG DELIVERY
8.3.4.2. NANOPARTICLE DRUG DELIVERY
8.3.4.3. NUCLEIC ACID DRUG DELIVERY
8.3.4.4. APTAMER DRUG DELIVERY
8.3.4.5. OTHERS
8.4 ANTISENSE RNA
8.4.1 BY MOLECULES
8.4.1.1. NUSINERSEN
8.4.1.2. INOTERSEN
8.4.1.3. ETEPLIRSEN
8.4.1.4. VOLANESORSEN
8.4.1.5. GOLODIRSEN
8.4.1.6. OTHERS
8.4.2 BY DRUGS
8.4.2.1. SPINRAZA
8.4.2.2. TEGSEDI
8.4.2.3. EXONDYS 51
8.4.2.4. OTHERS
8.4.3 BY MECHANISM
8.4.3.1. RNASE H-DEPENDENT
8.4.3.2. STERIC BLOCKER
9 GLOBAL ANTISENSE AND RNAI THERAPEUTICS TREATMENT MARKET, BY INDICATION
9.1 OVERVIEW
9.2 ONCOLOGY
9.2.1 GASTRIC CANCER
9.2.2 BREAST CANCER
9.2.3 LIVER CANCER
9.2.4 PANCREATIC CANCER
9.2.5 CERVICAL CANCER
9.2.6 LUNG CANCER
9.2.7 ENDOMETRIAL CANCERS
9.2.8 OTHERS
9.3 CARDIOVASCULAR DISEASES (CVDS)
9.3.1 HYPERCHYLOMICRONEMIA
9.3.2 HYPERTRIGLYCERIDEMIA
9.3.3 CHYLOMICRONEMIA
9.3.4 PARTIAL LIPODYSTROPHY
9.3.5 OTHERS
9.4 RESPIRATORY DISORDERS
9.4.1 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
9.4.2 ASTHMA
9.4.3 CYSTIC FIBROSIS
9.4.4 OTHERS
9.5 NEUROLOGICAL DISORDERS
9.5.1 DUCHENE MUSCULAR DYSTROPHY
9.5.2 FAMILIAL AMYLOID POLYNEUROPATHY & CARDIOMYOPATHY
9.5.3 SPINAL MUSCULAR ATROPHY
9.5.4 HUNTINGTON’S DISEASE
9.5.5 OTHERS
9.6 INFECTIOUS DISEASES
9.6.1 HEPATITIS A & B
9.6.2 HIV
9.6.3 HPV
9.6.4 INFLUENZA
9.6.5 RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION
9.6.6 OTHERS
9.7 OTHERS
10 GLOBAL ANTISENSE AND RNAI THERAPEUTICS TREATMENT MARKET, BY DELIVERY SYSTEM
10.1 OVERVIEW
10.2 BY TYPE
10.2.1 LIPID-BASED NANOPARTICLE DELIVERY SYSTEMS
10.2.1.1. LIPOSOMES
10.2.1.2. SOLID LIPID NANOPARTICLES
10.2.1.3. NANOSTRUCTURED LIPID CARRIERS
10.2.2 POLYMER-BASED DELIVERY
10.2.3 OTHER DELIVERY SYSTEMS
10.2.3.1. EXOSOMES
10.2.3.2. HIGH-DENSITY LIPOPROTEIN
10.3 BY TARGETED DELIVERY
10.3.1 APTAMER
10.3.2 PEPTIDE AND ANTIBODY
10.3.3 FOLATE
10.4 BY ROUTE OF ADMINISTRATION
10.4.1 PULMONARY DELIVERY
10.4.2 INTRAVENOUS INJECTIONS
10.4.3 INTRA-DERMAL
10.4.4 INTRAPERITONEAL
10.4.5 TOPICAL
10.4.6 OTHERS
11 GLOBAL ANTISENSE AND RNAI THERAPEUTICS TREATMENT MARKET, BY GENDER
11.1 OVERVIEW
11.2 MALE
11.3 FEMALE
12 GLOBAL ANTISENSE AND RNAI THERAPEUTICS TREATMENT MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 SPECIALTY CLINICS
12.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
12.5 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES
12.6 OTHERS
13 GLOBAL ANTISENSE AND RNAI THERAPEUTICS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.3.1 HOSPITAL PHARMACY
13.3.2 RETAIL PHARMACY
13.3.3 ONLINE PHARMACY
14 GLOBAL ANTISENSE AND RNAI THERAPEUTICS TREATMENT MARKET, BY REGION
GLOBAL ANTISENSE AND RNAI THERAPEUTICS TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.2 CANADA
14.1.3 MEXICO
14.2 EUROPE
14.2.1 GERMANY
14.2.2 U.K.
14.2.3 ITALY
14.2.4 FRANCE
14.2.5 SPAIN
14.2.6 RUSSIA
14.2.7 SWITZERLAND
14.2.8 TURKEY
14.2.9 BELGIUM
14.2.10 NETHERLANDS
14.2.11 DENMARK
14.2.12 SWEDEN
14.2.13 POLAND
14.2.14 NORWAY
14.2.15 FINLAND
14.2.16 REST OF EUROPE
14.3 ASIA-PACIFIC
14.3.1 JAPAN
14.3.2 CHINA
14.3.3 SOUTH KOREA
14.3.4 INDIA
14.3.5 SINGAPORE
14.3.6 THAILAND
14.3.7 INDONESIA
14.3.8 MALAYSIA
14.3.9 PHILIPPINES
14.3.10 AUSTRALIA
14.3.11 NEW ZEALAND
14.3.12 VIETNAM
14.3.13 TAIWAN
14.3.14 REST OF ASIA-PACIFIC
14.4 SOUTH AMERICA
14.4.1 BRAZIL
14.4.2 ARGENTINA
14.4.3 REST OF SOUTH AMERICA
14.5 MIDDLE EAST AND AFRICA
14.5.1 SOUTH AFRICA
14.5.2 EGYPT
14.5.3 BAHRAIN
14.5.4 UNITED ARAB EMIRATES
14.5.5 KUWAIT
14.5.6 OMAN
14.5.7 QATAR
14.5.8 SAUDI ARABIA
14.5.9 REST OF MIDDLE EAST AND AFRICA
14.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
15 GLOBAL ANTISENSE AND RNAI THERAPEUTICS TREATMENT MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15.5 MERGERS & ACQUISITIONS
15.6 NEW PRODUCT DEVELOPMENT & APPROVALS
15.7 EXPANSIONS
15.8 REGULATORY CHANGES
15.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
16 GLOBAL ANTISENSE AND RNAI THERAPEUTICS TREATMENT MARKET, COMPANY PROFILE
16.1 ALNYLAM PHARMACEUTICALS
16.1.1 COMPANY OVERVIEW
16.1.2 REVENUE ANALYSIS
16.1.3 GEOGRAPHIC PRESENCE
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 BENITEC BIOPHARMA LTD.
16.2.1 COMPANY OVERVIEW
16.2.2 REVENUE ANALYSIS
16.2.3 GEOGRAPHIC PRESENCE
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPEMENTS
16.3 GENE SIGNAL
16.3.1 COMPANY OVERVIEW
16.3.2 REVENUE ANALYSIS
16.3.3 GEOGRAPHIC PRESENCE
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPEMENTS
16.4 GLAXOSMITHKLINE PLC.
16.4.1 COMPANY OVERVIEW
16.4.2 REVENUE ANALYSIS
16.4.3 GEOGRAPHIC PRESENCE
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPEMENTS
16.5 IONIS PHARMACEUTICALS
16.5.1 COMPANY OVERVIEW
16.5.2 REVENUE ANALYSIS
16.5.3 GEOGRAPHIC PRESENCE
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPEMENTS
16.6 MARINA BIOSCIENCES
16.6.1 COMPANY OVERVIEW
16.6.2 REVENUE ANALYSIS
16.6.3 GEOGRAPHIC PRESENCE
16.6.4 PRODUCT PORTFOLIO
16.6.5 RECENT DEVELOPEMENTS
16.7 SANOFI S.A
16.7.1 COMPANY OVERVIEW
16.7.2 REVENUE ANALYSIS
16.7.3 GEOGRAPHIC PRESENCE
16.7.4 PRODUCT PORTFOLIO
16.7.5 RECENT DEVELOPEMENTS
16.8 ACUITAS THERAPEUTICS
16.8.1 COMPANY OVERVIEW
16.8.2 REVENUE ANALYSIS
16.8.3 GEOGRAPHIC PRESENCE
16.8.4 PRODUCT PORTFOLIO
16.8.5 RECENT DEVELOPEMENTS
16.9 ANTISENSE THERAPEUTICS LTD.
16.9.1 COMPANY OVERVIEW
16.9.2 REVENUE ANALYSIS
16.9.3 GEOGRAPHIC PRESENCE
16.9.4 PRODUCT PORTFOLIO
16.9.5 RECENT DEVELOPEMENTS
16.1 ARBUTUS BIOPHARMA
16.10.1 COMPANY OVERVIEW
16.10.2 REVENUE ANALYSIS
16.10.3 GEOGRAPHIC PRESENCE
16.10.4 PRODUCT PORTFOLIO
16.10.5 RECENT DEVELOPEMENTS
16.11 BIO-PATH HOLDINGS INC.
16.11.1 COMPANY OVERVIEW
16.11.2 REVENUE ANALYSIS
16.11.3 GEOGRAPHIC PRESENCE
16.11.4 PRODUCT PORTFOLIO
16.11.5 RECENT DEVELOPEMENTS
16.12 ARROWHEAD PHARMACEUTICALS
16.12.1 COMPANY OVERVIEW
16.12.2 REVENUE ANALYSIS
16.12.3 GEOGRAPHIC PRESENCE
16.12.4 PRODUCT PORTFOLIO
16.12.5 RECENT DEVELOPEMENTS
16.13 DICERNA PHARMACEUTICALS
16.13.1 COMPANY OVERVIEW
16.13.2 REVENUE ANALYSIS
16.13.3 GEOGRAPHIC PRESENCE
16.13.4 PRODUCT PORTFOLIO
16.13.5 RECENT DEVELOPEMENTS
16.14 GRADALIS
16.14.1 COMPANY OVERVIEW
16.14.2 REVENUE ANALYSIS
16.14.3 GEOGRAPHIC PRESENCE
16.14.4 PRODUCT PORTFOLIO
16.14.5 RECENT DEVELOPEMENTS
16.15 ICO THERAPEUTICS
16.15.1 COMPANY OVERVIEW
16.15.2 REVENUE ANALYSIS
16.15.3 GEOGRAPHIC PRESENCE
16.15.4 PRODUCT PORTFOLIO
16.15.5 RECENT DEVELOPEMENTS
16.16 VIRIDIAN THERAPEUTICS
16.16.1 COMPANY OVERVIEW
16.16.2 REVENUE ANALYSIS
16.16.3 GEOGRAPHIC PRESENCE
16.16.4 PRODUCT PORTFOLIO
16.16.5 RECENT DEVELOPEMENTS
16.17 OLIX PHARMACEUTICALS
16.17.1 COMPANY OVERVIEW
16.17.2 REVENUE ANALYSIS
16.17.3 GEOGRAPHIC PRESENCE
16.17.4 PRODUCT PORTFOLIO
16.17.5 RECENT DEVELOPEMENTS
16.18 APTOSE BIOSCIENCES INC.
16.18.1 COMPANY OVERVIEW
16.18.2 REVENUE ANALYSIS
16.18.3 GEOGRAPHIC PRESENCE
16.18.4 PRODUCT PORTFOLIO
16.18.5 RECENT DEVELOPEMENTS
16.19 REGULUS THERAPEUTICS
16.19.1 COMPANY OVERVIEW
16.19.2 REVENUE ANALYSIS
16.19.3 GEOGRAPHIC PRESENCE
16.19.4 PRODUCT PORTFOLIO
16.19.5 RECENT DEVELOPEMENTS
16.2 OCUPHIRE PHARMA, INC.
16.20.1 COMPANY OVERVIEW
16.20.2 REVENUE ANALYSIS
16.20.3 GEOGRAPHIC PRESENCE
16.20.4 PRODUCT PORTFOLIO
16.20.5 RECENT DEVELOPEMENTS
16.21 RXI PHARMACEUTICALS
16.21.1 COMPANY OVERVIEW
16.21.2 REVENUE ANALYSIS
16.21.3 GEOGRAPHIC PRESENCE
16.21.4 PRODUCT PORTFOLIO
16.21.5 RECENT DEVELOPEMENTS
16.22 ROCHE
16.22.1 COMPANY OVERVIEW
16.22.2 REVENUE ANALYSIS
16.22.3 GEOGRAPHIC PRESENCE
16.22.4 PRODUCT PORTFOLIO
16.22.5 RECENT DEVELOPEMENTS
16.23 SAREPTA THERAPEUTICS
16.23.1 COMPANY OVERVIEW
16.23.2 REVENUE ANALYSIS
16.23.3 GEOGRAPHIC PRESENCE
16.23.4 PRODUCT PORTFOLIO
16.23.5 RECENT DEVELOPEMENTS
16.24 SILENCE THERAPEUTICS PLC.
16.24.1 COMPANY OVERVIEW
16.24.2 REVENUE ANALYSIS
16.24.3 GEOGRAPHIC PRESENCE
16.24.4 PRODUCT PORTFOLIO
16.24.5 RECENT DEVELOPEMENTS
16.25 SIRNAOMICS INC.
16.25.1 COMPANY OVERVIEW
16.25.2 REVENUE ANALYSIS
16.25.3 GEOGRAPHIC PRESENCE
16.25.4 PRODUCT PORTFOLIO
16.25.5 RECENT DEVELOPEMENTS
16.26 CENIX BIOSCIENCE
16.26.1 COMPANY OVERVIEW
16.26.2 REVENUE ANALYSIS
16.26.3 GEOGRAPHIC PRESENCE
16.26.4 PRODUCT PORTFOLIO
16.26.5 RECENT DEVELOPEMENTS
16.27 NOVARTIS AG
16.27.1 COMPANY OVERVIEW
16.27.2 REVENUE ANALYSIS
16.27.3 GEOGRAPHIC PRESENCE
16.27.4 PRODUCT PORTFOLIO
16.27.5 RECENT DEVELOPEMENTS
16.28 PEPTIDREAM INC.
16.28.1 COMPANY OVERVIEW
16.28.2 REVENUE ANALYSIS
16.28.3 GEOGRAPHIC PRESENCE
16.28.4 PRODUCT PORTFOLIO
16.28.5 RECENT DEVELOPEMENTS
16.29 CUREVAC AG
16.29.1 COMPANY OVERVIEW
16.29.2 REVENUE ANALYSIS
16.29.3 GEOGRAPHIC PRESENCE
16.29.4 PRODUCT PORTFOLIO
16.29.5 RECENT DEVELOPEMENTS
16.3 ASTELLAS PHARMA INC.
16.30.1 COMPANY OVERVIEW
16.30.2 REVENUE ANALYSIS
16.30.3 GEOGRAPHIC PRESENCE
16.30.4 PRODUCT PORTFOLIO
16.30.5 RECENT DEVELOPEMENTS
17 CONCLUSION
18 QUESTIONNAIRE
19 ABOUT DATA BRIDGE MARKET RESEARCH
